In this paper, we present the biochemical and biological evaluation of N-arylmethyl-substituted iminoribitol derivatives as potential chemotherapeutic agents against trypanosomiasis. Previously, a library of 52 compounds was designed and synthesized as potent and selective inhibitors of Trypanosoma vivax inosine-adenosine-guanosine nucleoside hydrolase (IAG-NH). However, when the compounds were tested against bloodstream-form Trypanosoma brucei brucei, only one inhibitor, N-(9-deaza-adenin-9-yl)methyl-1,4-dideoxy- were investigated using RNA interference. The findings from all these studies showed that it is probably not sufficient to target only the nucleoside hydrolase activity to block the purine salvage pathway of T. b. brucei and that, therefore, it is possible that UAMC-00363 acts on an additional target.In the search for new selective trypanocidal drugs, it has been proposed that the purine metabolism of Trypanosoma brucei provides a valuable target. In contrast to mammals, all parasites are unable to synthesize purines de novo and rely instead on the purine salvage pathway (PSP) to obtain purines, which are essential for their survival. The PSP is essential for all stages of T. brucei. The following enzymes of the PSP in T. brucei brucei are described in the literature (Fig. 1): inosine-adenosine-guanosine nucleoside hydrolase (IAG-NH; EC.3.2.2.1) (33, 38), inosine-guanosine nucleoside hydrolase (IG-NH; EC 3.2.2.1) (32), methylthioadenosine phosphorylase (MTAP; EC 2.4.2.28) (43), adenine phosphoribosyltransferase (APRT; EC 2.4.2.7) (5), hypoxanthine-guanine phosphoribosyltransferase (HGPRT; EC 2.4.2.8) (36), and adenosine kinase (AK; EC 2.7.1.20) (5). Key enzymes in the PSP of T. brucei are the nucleoside hydrolases (NH; EC 3.2.2.1). In these parasites, purine bases are obtained by cleavage of the N-glycosidic bond of nucleosides by NH. In T. b. brucei, two types of NH are present: the purine nucleoside-specific IAG-NH, which prefers inosine, adenosine, and guanosine as substrates, and the 6-oxopurine-specific IG-NH, with high affinities for inosine and guanosine (30,32,38). It should be noted that NH activity is absent in mammalian cells. Therefore, NH may provide a good target for the development of new antitrypanosomal compounds (19). Consequently, this target has been investigated during the past decade, and potent inhibitors of NH have been developed. The immucillins (20,29) and N-arylmethyl-substituted iminoribitol derivatives (4,22,23,39) (Fig. 2) are the strongest inhibitors of T. vivax IAG-NH (TvIAG-NH) and T. b. brucei IAG-NH (TbbIAG-NH) known to date, with K i values in the low nanomolar range. Additionally, many of these inhibitors show selectivity with respect to the human nucleoside-cleaving enzyme human pu-* Corresponding author. Mailing address: